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ABSTRACT
PURPOSE: To evaluate the immunohistochemical expression of p16, Ki-67, p53 and Bcl-2 proteins in gastrointestinal stromal tumors 
(GIST); to assess the possible association between these variables and clinical and histopathological factors of cancer; and to check for 
prognostic value of these variables (survival and recurrence). 
METHODS: A sample of 55 patients treated surgically for GIST in three hospitals was studied. The surgically excised tumors were 
confirmed as GIST by KIT, vimentin, desmin S100 protein, CD117, 1A4 and CD34 assessment in paraffin blocks. 
RESULTS: Only 9 (16%) cases of GIST were positive for p53, p16 was positive among 43.6%; 80% of GISTs showed staining for 
Bcl-2. The proliferative index (expressed as the proportion of positive cells) assessed by immunohistochemical expression of Ki-67 was 
high in 49% of cases. Elevated Ki-67 scores were associated to high histological grade (p=0.0026) and mitosis index, MI (p=0.0001). 
High Ki-67 index was associated to death. Expression of p53, p16 and Bcl-2 did not correlate to morphological or clinical variables. 
CONCLUSIONS: Ki-67 immunohistochemical evaluation should be included in preoperative evaluation of GIST biopsies or surgical 
specimens as a prognostic tool for clinical staging; and all other proteins studied (Bcl-2, p53 and p16) did not play a role in GIST 
metabolic or carcinogenic process, remaining without prognostic value.
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RESUMO
OBJETIVO: Avaliar a expressão imunoistoquímica de p16, Ki-67, p53 e Bcl-2 proteínas em tumores gastrointestinais estromais 
(GIST); determinar a possível associação entre essas variáveis e fatores clínicos e histopatológicos de câncer, e para verificar o valor 
prognóstico destas variáveis (sobrevivência e recorrência).
MÉTODOS: Uma amostra de 55 pacientes tratados cirurgicamente para GIST em três hospitais foi estudada. Os tumores extirpados 
cirurgicamente foram confirmados como GIST por KIT, vimentina, proteína desmina S100, CD117, 1A4 e avaliação de CD34 em 
blocos de parafina.
RESULTADOS: Apenas nove (16%) casos de GIST foram positivos para p53, p16 foi positiva em 43,6%, 80% dos GIST apresentaram 
coloração para Bcl-2. O índice proliferativo (expresso como a proporção de células positivas), avaliado pela expressão imunoistoquímica 
de Ki-67, foi elevado em 49% dos casos. Escores de Ki-67 elevados foram associados com alto grau histológico (p=0,0026) e índice de 
mitose, MI (p=0,0001). Alto índice de Ki-67 foi associado à morte. Expressão da p53, p16 e Bcl-2 não se correlacionou com as variáveis 
morfológicas ou clínicas. 
CONCLUSÕES: A avaliação imunoistoquímica de Ki-67 deve ser incluída na avaliação pré-operatória de biópsias ou peças cirúrgicas 
de GIST como uma ferramenta prognóstica para o estadiamento clínico, e todas as outras proteínas estudadas (Bcl-2, p53 e p16) não 
desempenharam um papel no processo metabólico ou carcinogênico em GIST, mantendo-se sem valor prognóstico.
Descritores: Tumores do Estroma Gastrointestinal. Antígeno Ki-67. Imunoistoquímica. Taxa de sobrevida.
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Introduction
Gastrointestinal stromal tumors (GIST) are considered a 
rare entity, encompassing for 2.2% of gastric neoplasias, 13.9% 
in small intestine and only 0.1% of colon tumors. However, in the 
United States 3000 to 5000 new GIST cases are diagnosed yearly1. 
Before 1986 this entity was encompassed among gastrointestinal 
mesenchimal tumors. With the identification of KIT protein 
expression in these lesions, a novel malignant tumor referred as 
GIST was identified2,3.
In the 2001 consensus, immunopositivity was defined as 
a key element for the diagnosis of GIST, and the classification of 
malignancy is based on tumor size and mitotic count3-5. However, 
lack of uniform diagnostic criteria leaded to controversial 
epidemiological and survival data. Some tumors previously 
considered GIST could be diagnosed as other particular GI 
sarcomas (as leiomiosarcomas or schwannomas)3,6. Differential 
diagnosis among GIST and other muscular or neural tumors 
require therefore immunohistochemical assessment with standard 
profile including S100 protein, CD34, 1a4, desmin, and CD117 
(c-KIT) antibody, determinant of GIST diagnosis3. 
Only 5% of GISTs are sensitive to classic chemotherapy7 
and radiotherapy is ineffective in this particular entity. Surgical 
resection was the main therapeutic approach to GIST until 
mesylate imatinib (Glivec), a molecular target drug that blocks 
KIT signalization (STI-571)8, was available for adjuvant therapy 
in advanced or irressecable GIST cases7,9. 
However, it is still difficult to determine which cases 
will metastasis or present an aggressive behavior based uniquely 
in morphological variables. Several potential prognostic variables 
were assessed in GIST, such as DNA ploidy, protein expression 
(S100, CD34, VEGF, S-VEGF) and genetic alterations (deletion 
of exon 11) without reaching statistical significance and, more 
important, with lack of technical reproducibility. Recently, we 
evaluated the role of p53 and Ki-67 immunohistochemically with 
preliminary favorable results10. 
The objectives of this study are: 1) To evaluate the 
immunohistochemical expression of p16, Ki-67, p53 and Bcl-2 
proteins in 55 cases of GIST; 2) to assess the possible association 
between these variables and clinical and histopathological factors 
of breast cancer; and 3) to check for prognostic value of these 
variables, relating them to survival and recurrence.
Methods
A total of 55 samples of surgically excised GIST, 
diagnosed between February of 1992 and September of 2006, were 
retrospectively identified from the archives of the Department of 
Surgical Pathology of three university Hospitals of Sao Paulo, 
Brazil, and were included in this study. Ethics Committees of all 
the three institutions approved this study. 
Inclusion criteria were primary GIST tumors previously 
detected by immunohistochemical profile including KIT, vimentin, 
desmin, S100 protein, CD117, 1A4 and CD34 immunoreactivity 
assessment (as suggested by Fletcher et al.3); paraffin blocks 
and clinical data available for further analysis and tumors with 
no preoperative chemo or radiotherapy. GIST tumors had been 
graded according to the standard criteria3, and to morphological 
categories, presence of necrosis, mitotic index (50 high power 
camps, hpc), tumor width and histological type and grade. These 
variables were morphologically assessed in hematoxylin-eosin 
(HE) slides by two pathologists (AFL and RAN). Clinical, survival 
and recurrence rates were calculated based on the follow up of all 
patients until October 2006. 
Immunohistochemical assessment 
Representative tumor paraffin-embedded tissue blocks 
were cut into 5 micra slides. Immunohistochemistry analysis 
was performed on each tumor slide block for p53, p16, Bcl-
2 e Ki-67, with standard streptavidin ABC methodology. Two 
minutes of pressure cooking at pH 6.0 was used for antigen 
retrieval with p53 clone (1:x) (BioGenex Inc., San Ramon, CA, 
USA). Immunohistochemical essay with the tumor markers was 
performed using the antibodies and conditions shown in Table 1.
TABLE 1 - Immunohistochemical markers used to assess 
cell proliferation and apoptosis in gastrointestinal stroma tumor.
Antibody Clone Provider Recovery Detection Dilution
Bcl-2 124 DAKO Microwave Antimouse ABC 1:400
P53 DO-7 DAKO Pressure pan Envision-mouse 1:2000
P16 16P07 Neomarkers Microwave Envision-mouse 1:100
Ki67 MIB-1 DAKO Pressure pan Envision-mouse 1:300
For p53, p16, and Ki-67, nuclear expression was assessed 
by identification of nuclear brown staining of neoplastic cells for 
further analysis at the nuclear markers11-14. A semiquantitative 
method for nuclear immunohistochemical grading was used15. 
Bcl-2 showed a cytoplasmatic diffuse staining. A lesion 
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was designated as positive if at least 10% of true neoplastic tumor 
cells expressed the antibody studied15-17. In some tumors virtually 
every cell expresses the marker and others may show a focal or 
variable percentage of positive cells. 
Statistical analysis
Full clinical follow-up data, including presence of 
metastatic disease, were available for all GIST cases. Associations 
between p53, p16, Bcl-2 e Ki-67, immunoreactivity and clinic 
pathological parameters – including tumor size (as defined by 
TMN [tumor-node-metastasis] staging, 7th edition), tumor grade 
(as morphological criteria) local recurrence, and distant metastasis 
– were evaluated by Fisher’s exact test or chi-squared 2 test as 
appropriate. Mean age at diagnosis and positivity for p53, p16, Bcl-
2 e Ki-67 were compared using t test and Kolmogorov-Smirnov 
test. Survival analyses were conducted for overall survival (OS), 
disease-free survival (DFS), survival to metastases at specific 
sites, and time from first recurrence to death. DFS was defined as 
time to any type of recurrence, distant metastasis, or death from 
any cause. Survival curves were calculated using the Kaplan-
Meier method. Tests of differences in survival between groups 
were performed using the log-rank test and were expressed as 
hazard ratios (HRs), which were estimated using Cox regression. 
Cox regression analysis was also used to evaluate any independent 
effect of prognostic factors on DFS, OS, and survival from 
recurrence. Factors found to be significant (at a p value of less 
than 0.05) in the survival analysis, together with for p53, p16, Bcl-
2 e Ki-67 as the factors of principal interest, were included in the 
regression analyses. All tests were two-tailed, and 95% confidence 
intervals were presented where appropriate. All analyses were 
carried out using software SAS 9.1 (Statistical Analysis System, 
Cary, NC, USA).
Results
Clinical and morphological data 
Among the 55 studied patients, 13 died from the 
disease (23.6%) and 42 were alive (76.4%) at the last follow 
up assessment. Among the survivors, 34 had no sign of disease 
(80.9%) and 8 were currently presenting recurrence (14.5%). All 
clinical epidemiological and morphological data are disposed in 
Table 2. 
TABLE 2 - Clinical and demographic data on 
gastrointestinal stromal tumor (GIST) patients.
Characteristics GIST (n=55) %
Median age (range)
Gender
Male 27 49
Female 28 51
Age
Median 56
Maximum 87
Histological 
type
Fusiform 32 58
Epitelioid 15 27
Mixed 8 15
Site
Stomach 22 40
Small bowel 20 36
Retroperitonium 5 9
Colon 4 7
Others 4 7
Histological 
grade
High 33 60
Moderate 13 24
Low 9 16
Tumor size
Up to 5 cm 6 11
5 to 10 cm 22 40
More than 10 cm 27 49
The stomach was the most frequent affected organ 
(22 cases, or 40%). However, atypical locations as appendix, 
mesenterium, rectum and pelvis were represented with one case 
each (disposed as “others” in Table 2). Median tumor width 
was 12.78 cm (0.7 a 32 cm) with predominance of fusiform 
differentiation (32 or 58.1%). 
More than 20% of the cases were composed of high-
grade tumors (Table 2). Tumor necrosis was present in 31 cases 
(56.4%). High mitotic index (MI) (more than 10 mitosis per high 
power fields) was observed in 21 GIST cases (38%), while 8 
(12%) presented intermediary MI (5 to 9 mitosis per 50 hpf) and 
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27 (49%) only a low MI (up to 4 mitosis in 50 cpf). 
When all morphological and clinical variables were 
statistically analyzed altogether, necrosis was associated to tumor 
width (p=0.0032), to MI (p=0.0001) and also to histological grade 
(p=0.0013). Presence of necrosis was marginally associated to 
evolution to death and the also to the epithelioid variant, but it did 
not reach statistical value (p=0.0599 and p=0.0562, respectively).
Besides necrosis, MI was associated to evolution, to 
death (p=0.0153) and to the “stayed alive” (p=0.0099) conditions; 
and correlated to tumor width (p=0.0009) and histological grade 
(p=0.0001). Finally, histological grade was also associated to 
tumor width (p=0.0001) and evolution, since high histological 
grade patients’ survival was significantly shorter when compared 
to lower-grade patients (p=0.0163). 
p53, p16, Ki-67 and Bcl-2 expression
Preliminary diagnostic immunohistochemical profile 
of all tumors included analysis of desmin (seven positive cases, 
12.7%), S100 protein (17 stained cases, 30.1%), vimentin 
(almost all cases stained strongly, 49 or 89.1%), CD34 (reactivity 
present in 35 cases or 63.6%), and 1A4 expression (present in 22 
cases, 40%). These data were not significantly correlated to any 
morphological or clinical variables.
Only nine (16%) cases of GIST were positive for p53, 
and the proportion of neoplastic positive cells were largely variable 
among the positive cases. 
p16, however, was positive among 25 reactive cases 
(43.6%); with positivity in the majority of the transformed cells. 
Interestingly, more than 75% of GIST analyzed also showed 
staining for Bcl-2 (44 cases or 80%). 
According to the proliferative index, tumor cells were 
negative for Ki-67 in 27 cases (49%) and positive in the remaining 
28. 
Among the biological markers, Ki-67score reached 
significant correlation with other important prognostic variables. 
Higher Ki-67 scores were associated to high histological grade 
(p=0.0026 with Fisher test, p=0.007 with Kruskal-Wallis test) 
and MI (p=0.0001). Tumors with high Ki-67 indexes presented 
necrosis (p=0.0257) and p53 positive results (p=0.0018) more 
frequently. Moreover, a high Ki-67 index was associated to death: 
13 of 24 Ki-67-positive GIST patients died during the study and 
association to evolution was confirmed with Fisher and Kruskal-
Wallis tests (p=0.049 and p=0.01, respectively). Figure 1 shows 
the survival curves of positive and negative Ki-67 cases. 
FIGURE 1 - Survival curve of patients with GIST tumors and positive or 
negative for Ki-67 (Mib).
Expression of p53, p16 and Bcl-2 did not show any 
association and did not correlate to any morphological or clinical 
variables (Table 3). 
TABLE 3 - Statistical significance (p value) of the 
correlations between the variables.
Variables p16 Bcl-2 Ki-67 Degree Mitosis Necrosis Size Evolution
p53 0.3402 1.000 0.0018 0.5614 0.1446 0.8648 0.8524 0.5617
p16 - 0.5698 0.8460 0.3985 0.8913 0.2433 0.4944 0.2055
Bcl-2 - - 1.000 0.9302 0.2528 0.2766 0.5185 0.1454
Ki-67 - -- - 0.0026 < 0.001 0.0257 0.0991 0.0161
Histological 
grade
- - - - < 0.001 0.0013 < 0.001 0.1417
Mitosis - - - - - < 0.001 < 0.001 0.0202
Necrosis - - - - - - 0.0032 0.0872
Size - - - - - - - 0.7314
Discussion
The current prognostic classification in GIST is based 
in tumor width and mitotic index as proposed by Fletcher et 
al.3 However, the classical mitotic index evaluation requires 50 
high power camps and usually small samples are insufficient 
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to complete the analysis. Moreover, there are irregularities. For 
instance, fixation may shrink tumor size and mitoses may “go 
over” during fixation18. 
Recently, diagnostic approach to GIST started to 
include ultrasound-guided fine needle aspiration or core biopsy. 
Preliminary results from our group10 and also from Ando et al.19 
suggested that Ki-67 expression is a powerful prognostic tool 
for easy assess in smaller samples. The new Food and Drug 
Administration (FDA)-approved indication of imatinib mesylate 
in the adjuvant therapy turns biopsy specimens assessment 
necessary. Currently, there is no consensus in literature about the 
most suitable methodology for proliferation assessment and Ki-67 
expression evaluation in GIST. Besides the variation of reading 
and assessment methodologies, limit values for positive and 
negative results remain controversial20-24. 
We used a previously described method for Ki-67 
assessment (Allred method for estrogen receptor). By using 
a high score for intensity13, since it is assumed that it would be 
equivalent in all samples and not variable, adapted this method to 
proliferation assessment. Distribution remained with punctuation 
from 0 to 5, leading to an index from 4 to 8. The final result is 
expressed in crescent categories, very reproducible. One advantage 
is that it constitutes an easily understandable method among 
distinct observers, as in ER expression, and practical for clinical 
application. Another important feature of this approach is that it 
can be performed in biopsy specimens, therefore allowing the 
pathologist to have an idea of proliferation status before surgery. 
The strong correlation to other important prognostic variables, 
such as histological grade (p=0.0026), mitotic index (p=0.001) 
and presence of necrosis (p=0.0257) endorsed the potential clinical 
role of this Ki-67 index. Finally, the association of Ki-67 index to 
evolution (p=0.0161) was evidenced, demonstrating that higher 
Ki-67 index is associated to poor survival rate.
The evaluation of cell cycle-related proteins in neoplasms 
by immunohistochemistry has been included in prognostic staging 
in central nervous system25,26 and other tumors21,27-30. We verified if 
these same proteins could also play a prognostic role in GIST20,31.
Bcl-2 protein is highly expressed in many neoplasms 
and also in GIST. Our results confirmed that GISTs are Bcl-2 
expressing tumors. Classically, chemotherapy agents hit cells in 
an apoptosis pathway. In carcinomas and lymphomas, a higher 
contingent of apoptotic cells may represent a better response 
to chemotherapy30,32. Unlike many chemotherapeutic agents, 
imatinib mesylate, used in GIST is not based on a proliferating 
contingent of cells, but rather a blocking tyrosine kinase receptors 
and the further induction of cellular proliferation33. Therefore, 
Bcl-2 would not be useful to predict response to imatinib. Indeed, 
most of the studies could not associate the highly expressed Bcl-
2 to other prognostic factors or to drug response in GIST22-24,34. 
We confirmed that Bcl-2 assessment could not improve staging 
or prognosis assessment in GIST. The reason why Bcl-2 is so 
up regulated in GIST is not clear yet. One could speculate that 
uncontrolled proliferation in ultimately stable mesenchimal cells 
could trigger cell mechanisms to balance increasing population 
or cell transformation in GIST affects Bcl-2 gene regulation with 
protein stabilization and accumulation. Molecular assessment 
would be necessary to clarify this issue. 
Gene mutations in TP53 tumor-suppressor gene are 
one of the most common genetic alterations in human solid 
tumors. Loss of p53 protein function may increase the risk for 
carcinogenesis35,36. There are dozens of publications on p53 
expression in GIST with a large methodological variation among 
them. However, the series of patients are usually smaller than ours 
and the results are very heterogeneous, ranging from 0 to 100% 
of positive neoplastic cells. In five larger studies, comprehending 
more than 60 patients, p53 staining was present in less than 50% of 
neoplastic cells and prognostic value remained controversial35,36.
We found nine p53 positive GIST cases in 55 analyzed 
(16%), and p53 staining correlated to Ki-67 index, but not to any 
other clinical or morphological variable. The smaller contingent of 
p53 positive cells could mean that p53 alterations are not adamant 
to GIST early steps in carcinogenesis and may occur later in 
this process37,38. Also p53 deletion is not frequent and missense 
mutation seems confined to less than 50% of neoplastic cells39. 
The assessment of p16 protein in GIST is still incipient 
and three previous studies40-42 with positivity ranging from 34% 
and 62% assessed p16 by PCR, RNA and tissue microarray 
(TMA). We found 25 immunohistochemically positive cases 
(45.4%). Metilation of p16 gene was previously demonstrated by 
House et al.42 with may partially explain the diversion of results. 
Ki-67 protein is one of several factors involved in cell 
proliferation that may be assessed easily by immunohistochemistry. 
Ki-67 index reflects the proportion of cycling cells in a given 
population. In GIST, Ki-67 expression has been previously 
associated to morphological variables and also survival, but 
results are hardly comparable due to methodological different 
approach19,20,23,31.
Conclusions
The Ki-67 immunohistochemical evaluation should be 
included in preoperative evaluation of GIST biopsies or surgical 
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specimens as a prognostic tool for clinical staging. All other 
proteins studied (Bcl-2, p53 and p16) did not play a role in GIST 
metabolic or carcinogenic process, remaining without prognostic 
value. 
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